Nephria Bio signs exclusive agreement with Drexel University to license new "MXene" nanomaterial for future dialysis innovations News provided by Share this article Nephria Bio secures a key technology needed to develop wearable dialysis therapies Nephria is in close collaboration with EOFlow and Dr. Yury Gogotsi's lab at Drexel University PORTMOUTH, N.H., April 29, 2021 /PRNewswire/ -- On April 29, Nephria Bio, a privately held US corporation specializing in the development of innovative approaches to dialysis, announced that it signed a license agreement with Drexel University to transfer technology of new MXene nanomaterials. Through this license agreement, Nephria Bio, Inc. ('Nephria Bio') obtained the exclusive rights to use MXenes, invented and developed by Dr. Yury Gogotsi, PhD, Distinguished University and Bach professor in Drexel's College of Engineering who is a world leader in developing and studying MXenes. Nephria Bio plans to develop more efficient cartridges for dialysis centers and wearable dialysis devices with this technology transfer.